• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CROMSOURCE appoints Dr. Grzegorz Rychlik chief medical officer

CROMSOURCE appoints Dr. Grzegorz Rychlik chief medical officer

September 8, 2016
CenterWatch Staff

CROMSOURCE, an international CRO providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced the appointment of its new Chief Medical Officer Dr. Grzegorz Rychlik, and the expansion of its Medical Affairs Services department.

Dr. Rychlik has more than 26 years of experience in the pharmaceutical industry. He has held positions of increasing responsibility with sponsor and service companies of various sizes, including large, global organizations such as Pfizer, Novartis and Parexel, as well as virtual, small and mid-sized enterprises. Dr. Rychlik's most recent position was managing director with MRCD Pharma Services in the United Kingdom, and prior to that he served as medical director and chief medical officer for various organizations. His therapeutic expertise is closely aligned with CROMSOURCE's key areas of focus and expertise, namely oncology, ophthalmology, respiratory, cardiovascular, CNS and medical devices.

"The addition of an experienced and respected medical professional such as Greg strongly positions CROMSOURCEto be able to further support the increasingly complex product development needs of our clients. Additionally, as we expand our Medical Affairs offering we will optimize and grow our consultancy and medical services to better serveour clients," stated Dr. Oriana Zerbini, founder and chief executive officer of CROMSOURCE.

Dr. Troy McCall, CROMSOURCE chief operating officer, added, "We are very pleased to have Dr. Rychlik join the CROMSOURCE team. Under his leadership, CROMSOURCE will expand our medical monitoring, pharmacovigilance, and medical writing services to meet growing client needs. Having highly experienced and skilled individuals such as Greg within the Medical Affairs Services group will allow for the optimization and standardization of interdependent processes, while leveraging efficiencies and ensuring that the highest level of quality is delivered."

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing